Clinical trial NCT04446117: Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Official title: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Metastatic Prostate Cancer
Prostate Adenocarcinoma
Keywords: prostate cancer
castration-resistant prostate cancer
Lead sponsor: Exelixis
Sponsor class: INDUSTRY
Collaborators: name: Roche-Genentech
name: Takeda
First posted: 2020-06-24
Enrollment: 575
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Approximately 580 eligible subjects will be randomized in a 1:1 fashion to the experimental arm receiving cabozantinib and atezolizumab in combination (290) or to the control arm receiving a second NHT (290).
Primary purpose: TREATMENT

Brief summary: This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.

Detailed description: The primary objective of this study is to evaluate the efficacy of cabozantinib (XL184) in combination with atezolizumab versus a second NHT (abiraterone or enzalutamide) in subjects with mCRPC who have previously been treated with one, and only one, NHT (e.g. abiraterone, apalutamide, darolutamide, or enzalutamide) to treat metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic CRPC (M0 CRPC), or mCRPC, and who have measurable extrapelvic disease. The multiple primary efficacy endpoints comparing the experimental arm and control arm are Duration of Progression Free Survival (PFS) per RECIST 1.1 by Blinded Independent Radiology Committee (BIRC) and Duration of Overall Survival (OS). The secondary efficacy endpoint is Objective Response Rate (ORR) per RECIST 1.1 per BIRC.

Eligibility criteria: Inclusion Criteria:

* Men with histologically or cytologically confirmed adenocarcinoma of the prostate
* Prior treatment with one, and only one, NHT (eg, abiraterone, apalutamide, darolutamide, or enzalutamide) for castration-sensitive locally advanced (T3 or T4) or mCSPC, M0 CRPC, or mCRPC
* Surgical or medical castration, with serum testosterone ≤ 50 ng/dL (≤ 1.73 nmol/L) at screening
* Measurable (extrapelvic soft tissue) metastatic disease per Investigator assessment defined by at least one of the following: measurable visceral disease (eg, adrenal, kidney, liver, lung, pancreas, spleen) per RECIST 1.1; OR measurable extrapelvic adenopathy (ie, adenopathy above the aortic bifurcation)
* Progressive disease at study entry as defined by specific criteria for prostate specific antigen (PSA) progression OR soft tissue disease progression in the opinion of the Investigator (Note: subjects with bone disease progression alone are not eligible)
* Age ≥ 18 years old or meeting country definition of adult, whichever is older, on the day of consent
* ECOG performance status of 0 or 1
* Recovery to baseline or ≤ Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) v5 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy in the opinion of the Investigator
* Adequate organ and marrow function based upon specific laboratory assessments obtained within 21 days prior to randomization
* Understanding and ability to comply with protocol requirements

Exclusion Criteria:

* Any prior nonhormonal therapy initiated for the treatment of mCRPC
* Receipt of abiraterone within 1 week; cyproterone within 10 days; or flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen-receptor inhibitors within 2 weeks before randomization
* Radiation therapy within 4 weeks (2 weeks for bone metastases) prior to randomization (subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible)
* Known brain metastases or cranial epidural disease unless adequately treated and clinically stable at least 4 weeks prior to randomization
* Symptomatic or impending spinal cord compression or cauda equina syndrome
* Concomitant anticoagulation with oral anticoagulants (some specific exceptions apply)
* Administration of a live, attenuated vaccine within 30 days prior to randomization
* Systematic treatment with, or any condition requiring, either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to randomization
* Uncontrolled, significant intercurrent or recent illness
* Major surgery within 4 weeks prior to randomization
* Corrected QT interval calculated by the Fridericia formula (QTcF) \> 480 ms per ECG within 21 days before randomization
* Inability or unwillingness to swallow pills or receive IV administration
* Previously identified allergy or hypersensitivity to components of the study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies
* Any other active malignancy at time of randomization or diagnosis of another malignancy within 2 years prior to randomization that requires active treatment (some exceptions apply such as locally curable cancers that have apparently been cured).

Primary outcomes:
measure: Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1)
timeFrame: Approximately 21 months after the first subject is randomized.
measure: Duration of Overall Survival (OS)
timeFrame: Approximately 37 months after the first subject is randomized
Secondary outcomes:
measure: Objective response rate (ORR)
timeFrame: Approximately 37 months after the first subject is randomized
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Exelixis Clinical Site #4
state: Arizona
city: Duarte
country: United States
facility: Exelixis Clinical Site #42
state: California
city: Fullerton
country: United States
facility: Exelixis Clinical Site #2
state: California
city: La Jolla
country: United States
facility: Exelixis Clinical Site #224
state: California
city: San Diego
country: United States
facility: Exelixis Clinical Site #114
state: California
city: Santa Monica
country: United States
facility: Exelixis Clinical Site #125
state: California
city: Stanford
country: United States
facility: Exelixis Clinical Site #245
state: California
city: Aurora
country: United States
facility: Exelixis Clinical Site #91
state: Colorado
city: Denver
country: United States
facility: Exelixis Clinical Site #14
state: Colorado
city: New Haven
country: United States
facility: Yale University School of Medicine
state: Connecticut
city: New Haven
country: United States
facility: Yale University, School of Medicine
state: Connecticut
city: Miami
country: United States
facility: Exelixis Clinical Site #108
state: Florida
city: Atlanta
country: United States
facility: Winship Cancer Institute of Emory University
state: Georgia
city: Westwood
country: United States
facility: Exelixis Clinical Site #215
state: Kansas
city: Louisville
country: United States
facility: Exelixis Clinical Site #242
state: Kentucky
city: Baltimore
country: United States
facility: Exelixis Clinical Site #6
state: Maryland
city: Detroit
country: United States
facility: Non-participating Site
state: Michigan
city: Rochester
country: United States
facility: Exelixis Clinical Site #203
state: Minnesota
city: Omaha
country: United States
facility: Exelixis Clinical Site #19
state: Nebraska
city: Las Vegas
country: United States
facility: Exelixis Clinical Site #144
state: Nevada
city: East Brunswick
country: United States
facility: Exelixis Clinical Site #123
state: New Jersey
city: Lawrenceville
country: United States
facility: Non-participating Site
state: New Jersey
city: Bronx
country: United States
facility: Exelixis Clinical Site #198
state: New York
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
city: Cleveland
country: United States
facility: Exelixis Site #159
state: Ohio
city: Oklahoma City
country: United States
facility: Exelixis Clinical Site #221
state: Oklahoma
city: Philadelphia
country: United States
facility: Exelixis Clinical Site #18
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Exelixis Clinical Site #201
state: Pennsylvania
city: Nashville
country: United States
facility: Exelixis Clinical Site #1
state: Tennessee
city: Houston
country: United States
facility: Exelixis Clinical Site #5
state: Texas
city: Houston
country: United States
facility: Exelixis Clinical Site #177
state: Texas
city: Houston
country: United States
facility: Exelixis Clinical Site #259
state: Texas
city: Temple
country: United States
facility: Exelixis Clinical Site #41
state: Texas
city: Salt Lake City
country: United States
facility: Exelixis Clinical Site #67
state: Utah
city: Roanoke
country: United States
facility: Exelixis Clinical Site #143
state: Virginia
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Exelixis Clinical Site #122
state: Buenos Aires
city: Mar Del Plata
country: Argentina
facility: Exelixis Clinical Site #120
state: Buenos Aires
city: Pergamino
country: Argentina
facility: Exelixis Site #170
state: Buenos Aires
city: Córdoba
country: Argentina
facility: Exelixis Clinical Site #210
state: Cordoba
city: Viedma
country: Argentina
facility: Exelixis Clinical Site #152
state: Rio Negro
city: Rosario
country: Argentina
facility: Exelixis Clinical Site #183
state: Santa Fe
city: Rosario
country: Argentina
facility: Exelixis Clinical #261
state: Santa Fe
city: Buenos Aires
country: Argentina
facility: Exelixis Clinical Site #200
city: Caba
country: Argentina
facility: Exelixis Clinical Site #256
city: Ciudad Autonoma de Buenos Aire
country: Argentina
facility: Exelixis Clinical Site #44
city: La Rioja
country: Argentina
facility: Exelixis Clinical Site #105
city: San Juan
country: Argentina
facility: Exelixis Clinical Site #124
city: San Salvador De Jujuy
country: Argentina
facility: Exelixis Clinical Site #101
city: Garran
country: Australia
facility: Exelixis Clinical Site #151
state: Australian Capital Territory
city: Port Macquarie
country: Australia
facility: Exelixis Clinical Site #252
state: New South Wales
city: Saint Leonards
country: Australia
facility: Exelixis Clinical Site #175
state: New South Wales
city: Sydney
country: Australia
facility: Exelixis Clinical Site # 189
state: New South Wales
city: Wollongong
country: Australia
facility: Exelixis Site #162
state: New South Wales
city: Chermside
country: Australia
facility: Exelixis Clinical Site #253
state: Queensland
city: Launceston
country: Australia
facility: Exelixis Clinical Site #103
state: Tasmania
city: Ballarat
country: Australia
facility: Exelixis Clinical Site #79
state: Victoria
city: Frankston
country: Australia
facility: Exelixis Clinical Site #95
state: Victoria
city: Geelong
country: Australia
facility: Exelixis Clinical #262
state: Victoria
city: Melbourne
country: Australia
facility: Exelixis Clinical Site #53
state: Victoria
city: Saint Albans
country: Australia
facility: Exelixis Clinical Stie #260
state: Victoria
city: Adelaide
country: Australia
facility: Exelixis Clinical Site #115
city: Box Hill
country: Australia
facility: Exelixis Clinical Site #149
city: Linz
country: Austria
facility: Exelixis Clinical Site #156
state: Oberösterreich
city: Linz
country: Austria
facility: Exelixis Site #158
state: Oberösterreich
city: Wien
country: Austria
facility: Exelixis Clinical Site #218
city: Bonheiden
country: Belgium
facility: Exelixis Clinical Site #126
state: Antwerpen
city: Gent
country: Belgium
facility: Exelixis Clinical Site #39
state: Oost-Vlaanderen
city: Brussels
country: Belgium
facility: Exelixis Clinical Site #141
city: Roeselare
country: Belgium
facility: Exelixis Site #165
city: Curitiba
country: Brazil
facility: Exelixis Clinical Site #204
state: Parana
city: Curitiba
country: Brazil
facility: Exelixis Site #163
state: Paraná
city: Porto Alegre
country: Brazil
facility: Exelixis Site #157
state: Rio Grande Do Sul
city: Rio De Janeiro
country: Brazil
facility: Exelixis Clinical Site #171
state: RJ
city: Blumenau
country: Brazil
facility: Exelixis Clinical Site #132
state: Santa Catarina
city: Campinas
country: Brazil
facility: Exelixis Clinical Site #191
state: Sao Paulo
city: Sao Paulo
country: Brazil
facility: Exelixis Site #161
state: SP
city: Ribeirão Preto
country: Brazil
facility: Exelixis Clinical Site #128
state: São Paulo
city: São José Do Rio Preto
country: Brazil
facility: Exelixis Clinical Site #106
state: São Paulo
city: Barretos
country: Brazil
facility: Exelixis Clinical Site #154
city: Fortaleza
country: Brazil
facility: Exelixis Clinical Site #140
city: Porto Alegre
country: Brazil
facility: Exelixis Clinical Site #153
city: Ribeirão Preto
country: Brazil
facility: Exelixis Clinical Site #145
city: Santa Cruz Do Sul
country: Brazil
facility: Exelixis Clinical Site #116
city: Edmonton
country: Canada
facility: Exelixis Clinical Site #69
state: Alberta
city: Kelowna
country: Canada
facility: Exelixis Clinical Site #112
state: British Columbia
city: Moncton
country: Canada
facility: Exelixis Clinical Site #147
state: New Brunswick
city: Hamilton
country: Canada
facility: Exelixis Clinical Site #83
state: Ontario
city: London
country: Canada
facility: Exelixis Clinical Site #127
state: Ontario
city: Oakville
country: Canada
facility: Exelixis Clinical Site #7
state: Ontario
city: Granby
country: Canada
facility: Exelixis Clinical Site #178
state: Quebec
city: Montréal
country: Canada
facility: Exelixis Site #160
state: Quebec
city: Viña del Mar
country: Chile
facility: Exelixis Clinical Site #247
state: Región De Valparaíso
city: Santiago de Chile
country: Chile
facility: Exelixis Clinical Site #139
state: Región Metropolitana De Santiago
city: Santiago
country: Chile
facility: Exelixis Clinical #263
state: Región Metropolitana
city: Providencia
country: Chile
facility: Exelixis Clinical Site #142
city: Recoleta
country: Chile
facility: Exelixis Clinical Site #148
city: Santiago
country: Chile
facility: Exelixis Clinical Site #90
city: Temuco
country: Chile
facility: Exelixis Clinical Site #113
city: Valparaíso
country: Chile
facility: Exelixis Clinical Site #119
city: Praha 2
country: Czechia
facility: Exelixis Clinical Site #63
state: Praha
city: Brno
country: Czechia
facility: Exelixis Clinical Site #129
city: Olomouc
country: Czechia
facility: Exelixis Clinical Site #130
city: Praha 2
country: Czechia
facility: Exelixis Clinical Site #80
city: Praha 8
country: Czechia
facility: Exelixis Clinical Site #47
city: Praha
country: Czechia
facility: Exelixis Clinical Site #31
city: Brest
country: France
facility: Exelixis Clinical Site #134
city: Clermont-Ferrand
country: France
facility: Exelixis Clinical Site #77
city: Dijon cedex
country: France
facility: Exelixis Clinical Site #155
city: Hyères
country: France
facility: Exelixis Clinical Site #74
city: La Roche-sur-Yon Cedex 9
country: France
facility: Exelixis Clinical Site #222
city: Nîmes
country: France
facility: Exelixis Clinical Site #146
city: Paris
country: France
facility: Exelixis Clinical Site #38
city: Quimper
country: France
facility: Exelixis Clinical Site #66
city: Reims
country: France
facility: Exelixis Clinical Site #214
city: Saint-Grégoire
country: France
facility: Exelixis Clinical Site #135
city: Strasbourg
country: France
facility: Exelixis Clinical Site #213
city: Strasbourg
country: France
facility: Exelixis Clinical Site #36
city: Toulouse
country: France
facility: Exelixis Clinical Site #73
city: Toulouse
country: France
facility: Exelixis Clinical Site #85
city: Vandoeuvre les nancy
country: France
facility: Exelixis Clinical Site #230
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #16
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #9
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #10
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #11
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #15
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #8
city: Nürtingen
country: Germany
facility: Exelixis Clinical Site #176
state: Baden-Wuerttemberg
city: Gutersloh
country: Germany
facility: Exelixis Clinical Site #98
state: Nordrhein-Westfalen
city: Duisburg
country: Germany
facility: Exelixis Clinical Site #180
state: North Rhine-Westphalia
city: Münster
country: Germany
facility: Exelixis Clinical Site #179
state: North Rhine-Westphalia
city: Lübeck
country: Germany
facility: Exelixis Clinical Site #185
state: Schleswig-Holstein
city: Berlin
country: Germany
facility: Exelixis Clinical Site #227
city: Hamburg
country: Germany
facility: Exelixis Clinical Site #239
city: Hannover
country: Germany
facility: Exelixis Clinical Site #273
city: Tübingen
country: Germany
facility: Exelixis Clinical Site #136
city: Athens
country: Greece
facility: Exelixis Clinical Site #238
state: Attica
city: Cholargós
country: Greece
facility: Exelixis Clinical Site #93
state: Attica
city: Maroussi
country: Greece
facility: Exelixis Clinical Site #202
state: Attica
city: Maroúsi
country: Greece
facility: Exelixis Clinical Site #92
state: Attica
city: Nea Kifisia
country: Greece
facility: Exelixis Clinical Site #244
state: Attica
city: Néo Fáliro
country: Greece
facility: Exelixis Clinical Site #99
state: Attica
city: Heraklion
country: Greece
facility: Exelixis Clinical Site #45
state: Crete
city: Thessaloníki
country: Greece
facility: Exelixis Clinical Site #64
state: Macedonia
city: Larissa
country: Greece
facility: Exelixis Clinical Site #97
state: Thessaly
city: Budapest
country: Hungary
facility: Exelixis Clinical Site #118
city: Budapest
country: Hungary
facility: Exelixis Clinical Site #207
city: Budapest
country: Hungary
facility: Exelixis Clinical Site #57
city: Budapest
country: Hungary
facility: Exelixis Clinical Site #109
city: Debrecen
country: Hungary
facility: Exelixis Clinical Site #240
city: Gyula
country: Hungary
facility: Exelixis site #167
city: Haifa
country: Israel
facility: Exelixis Clinical Site #55
city: Jerusalem
country: Israel
facility: Exelixis Clinical Site #27
city: Petah tikva
country: Israel
facility: Exelixis Clinical Site #150
city: Ramat Gan
country: Israel
facility: Exelixis Clinical Site #117
city: Safed
country: Israel
facility: Exelixis Clinical Site #30
city: Tel Aviv
country: Israel
facility: Exelixis Clinical Site #35
city: Meldola
country: Italy
facility: Exelixis Site #168
state: FC
city: Rozzano
country: Italy
facility: Exelixis Clinical Site #246
state: Milano
city: Sondrio
country: Italy
facility: Exelixis Site #156
state: SO
city: Trento
country: Italy
facility: Exelixis Clinical Site #199
state: Trentino
city: Ancona
country: Italy
facility: Exelixis Clinical Site #217
city: Firenze
country: Italy
facility: Exelixis Clinical Site #121
city: Milano
country: Italy
facility: Exelixis Clinical Site #258
city: Milan
country: Italy
facility: Exelixis Clinical Site #192
city: Parma
country: Italy
facility: Exelixis Clinical #267
city: Pavia
country: Italy
facility: Exelixis Clinical Site #237
city: Perugia
country: Italy
facility: Exelixis Clinical Site #107
city: Pisa
country: Italy
facility: Exelixis Clinical #269
city: Roma
country: Italy
facility: Exelixis Clinical Site #62
city: Roma
country: Italy
facility: Exelixis Clinical Site #234
city: Terni
country: Italy
facility: Exelixis Clinical Site #96
city: Toyota-shi
country: Japan
facility: Exelixis Clinical Site #232
state: Aichi
city: Akita-Shi
country: Japan
facility: Exelixis Clinical Site #100
state: Akita
city: Hirosaki
country: Japan
facility: Exelixis Clinical Site #104
state: Aomori
city: Kashiwa-shi
country: Japan
facility: Exelixis Clinical Site #43
state: Chiba
city: Sakura-shi
country: Japan
facility: Exelixis Clinical Site #54
state: Chiba
city: Sapporo
country: Japan
facility: Exelixis Clinical Site #72
state: Hokkaido
city: Sapporo
country: Japan
facility: Exelixis Clinical Site #37
state: Hokkaido
city: Kobe
country: Japan
facility: Exelixis Clinical Site #70
state: Hyogo
city: Kobe
country: Japan
facility: Exelixis Clinical Site #52
state: Hyogo
city: Kita-gun
country: Japan
facility: Exelixis Clinical Site #84
state: Kagawa
city: Sagamihara
country: Japan
facility: Exelixis Clinical Site #68
state: Kanagawa
city: Yokohama-shi
country: Japan
facility: Exelixis Clinical Site #22
state: Kanagawa
city: Natori-shi
country: Japan
facility: Exelixis Clinical Site #211
state: Miyagi
city: Chuo-Ku
country: Japan
facility: Exelixis Clinical Site #88
state: Osaka-shi
city: Hidaka
country: Japan
facility: Exelixis Clinical Site #51
state: Saitama
city: Shizuoka City
country: Japan
facility: Exelixis Clinical Site #216
state: Shizuoka
city: Shinjuku-Ku
country: Japan
facility: Exelixis Clinical Site #65
state: Tokyo
city: Ube
country: Japan
facility: Exelixis Clinical Site #61
state: Yamaguchi
city: Chiba
country: Japan
facility: Exelixis Clinical Site #78
city: Fukuoka
country: Japan
facility: Exelixis Clinical Site #209
city: Nagano
country: Japan
facility: Exelixis Clinical Site #26
city: Tokyo
country: Japan
facility: Exelixis Clinical Site #75
city: Wakayama
country: Japan
facility: Exelixis Clinical Site #32
city: Ōsaka-sayama
country: Japan
facility: Exelixis Clinical Site #81
city: Junggu
country: Korea, Republic of
facility: Exelixis Clinical Site #20
state: Daejeon
city: Goyang-si
country: Korea, Republic of
facility: Exelixis Clinical Site #49
state: Gyeonggi-do
city: Seongnam-si
country: Korea, Republic of
facility: Exelixis Clinical Site #60
state: Gyeonggi-Do
city: Hwasun
country: Korea, Republic of
facility: Exelixis Clinical Site #34
state: Jeollanam-do
city: Busan
country: Korea, Republic of
facility: Exelixis Clinical Site #58
city: Busan
country: Korea, Republic of
facility: Exelixis Clinical Site #24
city: Daegu
country: Korea, Republic of
facility: Exelixis Clinical Site #94
city: Daegu
country: Korea, Republic of
facility: Exelixis Clinical Site #21
city: Gwangju
country: Korea, Republic of
facility: Exelixis Clinical Site #40
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #59
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #46
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #25
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #48
city: Tuxtla Gutiérrez
country: Mexico
facility: Exelixis Clinical Site #206
state: Chiapas
city: Mexico City
country: Mexico
facility: Exelixis Clinical Site #187
state: Distrito Federal
city: Leon
country: Mexico
facility: Exelixis Clinical Site #254
state: Guanajuato
city: Guadalajara
country: Mexico
facility: Exelixis Clinical Site #212
state: Jalisco
city: Guadalajara
country: Mexico
facility: Exelixis Clinical Site #173
state: Jalisco
city: Zapopan
country: Mexico
facility: Exelixis Clinical Site #219
state: Jalisco
city: Monterrey
country: Mexico
facility: Exelixis Clinical Site #257
state: Nuevo Leon
city: Querétaro
country: Mexico
facility: Exelixis Clinical Site #172
state: Queretaro
city: Querétaro
country: Mexico
facility: Exelixis Clinical Site #182
state: Queretaro
city: San Luis Potosí
country: Mexico
facility: Exelixis Clinical Site #250
state: San Luis Potosi
city: San Luis Potosí
country: Mexico
facility: Exelixis Clinical Site #184
state: San Luis Potosi
city: Culiacán
country: Mexico
facility: Exelixis Clinical Site #208
state: Sinaloa
city: Mexico City
country: Mexico
facility: Exelixis Clinical Site #174
city: Puebla
country: Mexico
facility: Exelixis Clinical Site #272
city: Otwock
country: Poland
facility: Exelixis Clinical Site #243
state: Mazowieckie
city: Bydgoszcz
country: Poland
facility: Exelixis Clinical Site #82
city: Poznań
country: Poland
facility: Exelixis Clinical Site #89
city: Łódź
country: Poland
facility: Exelixis Clinical #268
city: Braga
country: Portugal
facility: Exelixis Clinical Site #110
city: Guimarães
country: Portugal
facility: Exelixis Clinical Site #188
city: Lisboa
country: Portugal
facility: Exelixis Site #164
city: Lisboa
country: Portugal
facility: Exelixis Clinical Site #197
city: Loures
country: Portugal
facility: Exelixis Clinical Site #196
city: Porto
country: Portugal
facility: Exelixis Clinical Site #56
city: Porto
country: Portugal
facility: Exelixis Clinical Site #223
city: Vila Real
country: Portugal
facility: Exelixis Clinical Site #193
city: Moscow
country: Russian Federation
facility: Exelixis Site #166
city: Saint Petersburg
country: Russian Federation
facility: Exelixis Clinical Site #137
city: Saint Petersburg
country: Russian Federation
facility: Exelixis Clinical Site #195
city: Singapore
country: Singapore
facility: Exelixis Clinical Site #50
city: Singapore
country: Singapore
facility: Exelixis Clinical Site #87
city: Singapore
country: Singapore
facility: Exelixis Clinical Site #181
city: Elche
country: Spain
facility: Exelixis Clinical Site #229
state: Alicante
city: Oviedo
country: Spain
facility: Exelixis Clinical Site #225
state: Asturias
city: Manresa
country: Spain
facility: Exelixis Clinical Site #12
state: Barcelona
city: Palma De Mallorca
country: Spain
facility: Exelixis Clinical Site #220
state: Islas Baleares
city: Santiago de Compostela
country: Spain
facility: Exelixis Clinical Site #233
state: La Coruna
city: Alcorcón
country: Spain
facility: Exelixis Clinical Site #17
state: Madrid
city: Badalona
country: Spain
facility: Exelixis Clinical Site #274
city: Barcelona
country: Spain
facility: Exelixis Clinical Site #228
city: Barcelona
country: Spain
facility: Exelixis Clinical Site #23
city: Barcelona
country: Spain
facility: Exelixis Clinical Site #255
city: Barcelona
country: Spain
facility: Exelixis Clinical Site #190
city: Cadiz
country: Spain
facility: Exelixis Clinical Site #226
city: Córdoba
country: Spain
facility: Exelixis Clinical Site #33
city: Lugo
country: Spain
facility: Exelixis Clinical Site #28
city: Madrid
country: Spain
facility: Exelixis Clinical Site #131
city: Madrid
country: Spain
facility: Exelixis Clinical Site #248
city: Madrid
country: Spain
facility: Exelixis Clinical Site #236
city: Madrid
country: Spain
facility: Exelixis Clinical Site #251
city: Madrid
country: Spain
facility: Exelixis Clinical Site #13
city: Málaga
country: Spain
facility: Exelixis Clinical #270
city: Sevilla
country: Spain
facility: Exelixis Clinical Site #29
city: Kaohsiung
country: Taiwan
facility: Exelixis Clinical #266
city: Kaohsiung
country: Taiwan
facility: Exelixis Clinical Site #138
city: Taichung City
country: Taiwan
facility: Exelixis Clinical Site #86
city: Taichung
country: Taiwan
facility: Exelixis Clinical Site #133
city: Tainan City
country: Taiwan
facility: Exelixis Clinical Site #271
city: Tainan
country: Taiwan
facility: Exelixis Clinical Site #111
city: Taipei city
country: Taiwan
facility: Exelixis Clinical #264
city: Taoyuan
country: Taiwan
facility: Exelixis Clinical #265
city: Dnipro
country: Ukraine
facility: Exelixis Clinical Site #102
city: Dnipro
country: Ukraine
facility: Exelixis Clinical Site #186
city: Kyiv
country: Ukraine
facility: Exelixis Clinical Site #76
city: Luts'k
country: Ukraine
facility: Exelixis Clinical Site #71
city: London
country: United Kingdom
facility: Exelixis Clinical Site #205
state: England
city: Surrey Quays
country: United Kingdom
facility: Exelixis Clinical Site #235
state: England
city: Taunton
country: United Kingdom
facility: Exelixis Clinical Site #241
state: England
city: Blackburn
country: United Kingdom
facility: Exelixis Clinical Site #249
state: Lancashire
city: Northwood
country: United Kingdom
facility: Exelixis Clinical Site #231
state: Middlesex
city: Swansea
country: United Kingdom
facility: Exelixis Clinical Site #194
state: Wales
Study officials:
References:
citation: Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17.